Starling Oncology Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Starling Oncology Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- STLN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001799191
Board of directors
-
Anne McGeorge · DirectorSince 2023
-
Brad Hively · Director · Chief Executive OfficerSince 2023
-
Gabriel Ling · DirectorSince 2023
-
Karen Marie Johnson · DirectorSince 2023
-
Maeve O'Meara · DirectorSince 2023
-
Mark L. Pacala · DirectorSince 2023
-
Mohit Kaushal · DirectorSince 2023
-
Ravi Yang Sarin · DirectorSince 2023
-
Richard A. Barasch · DirectorSince 2023
Chief executives
Brad Hively
· Chief Executive Officer
Dates unknown
Board connections
2 of this board's directors also sit on 2 other boards.
- via Richard A. Barasch
- via Anne McGeorge
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2025 | Richard A. Barasch Director | Derivative conversion | +620,400 | — | — |
| Jun 17, 2025 | Richard A. Barasch Director | In-the-money exercise | +679,224 | $1.20 | $815,069 |
| Jun 17, 2025 | Richard A. Barasch Director | Derivative conversion | +159,500 | — | — |
| Jun 17, 2025 | Richard A. Barasch Director | Shares withheld for tax | −311,128 | $2.62 | $815,155 |
| Jun 5, 2025 | M33 Growth I GP LLC Director, 10% owner | Open-market sale | −673,676 | $3.05 | $2,054,712 |
| Jun 5, 2025 | M33 Growth I GP LLC Director, 10% owner | Open-market sale | −76,324 | $3.05 | $232,788 |
| Jun 3, 2025 | Brad Hively Director | Option exercise | +684,528 | $0.85 | $581,849 |
| Jun 3, 2025 | Brad Hively Director | Option exercise | +105,320 | $0.48 | $50,554 |
| Jun 3, 2025 | Brad Hively Director | Option exercise | +131,297 | $1.87 | $245,525 |
| Jun 3, 2025 | Brad Hively Director | Option exercise | +946,460 | $0.85 | $804,491 |
| Jun 3, 2025 | Brad Hively Director | Open-market sale | −1,867,605 | $2.87 | $5,360,026 |
| Jun 3, 2025 | Brad Hively Director | Open-market sale | −108,532 | $2.87 | $311,487 |
| Mar 26, 2025 | M33 Growth I L.P. Director, 10% owner | Grant or award | +2,716,898 | $1.04 | $2,825,574 |
| Mar 26, 2025 | Virnich Daniel Officer (Chief Executive Officer) | Open-market purchase | +22,640 | $1.04 | $23,546 |
| Mar 26, 2025 | Podnos Yale Officer (Chief Medical Officer) | Open-market purchase | +9,056 | $1.04 | $9,418 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.